Subhendu Basu
Chief Executive Officer Telum Therapeutics
Seminars
Wednesday 25th March 2026
Reviving Confidence in Lysins Through Next-Generation Engineering to Deliver Real Therapies Against Resistant Infections
3:30 pm
- Demonstrating how next-generation lysins achieve rapid, contact-driven bacterial killing with minimal resistance potential, while leveraging advanced protein engineering to reduce immunogenicity and enhance in vivo stability
- Translating lessons from earlier clinical attempts into a more predictive development pathway, emphasizing physiologically relevant in vivo models over serum-based assays to design smarter, risk-reduced clinical trials
- Highlighting how computational design, rational candidate selection and pragmatic early-access pathways are converging to unlock a truly viable route to clinical deployment of lysin therapeutics
